Tazobactum%252525252525252525252525252525252525252525252525252525252520piperacillin

# Piperacillin/Tazobactam ## Overview Piperacillin/tazobactam is a combination antibiotic consisting of piperacillin, a broad-spectrum penicillin antibiotic, and tazobactam, a beta-lactamase inhibitor. Tazobactam protects piperacillin from degradation by many bacterial beta-lactamases, extending its spectrum of activity. ## Primary Indications * Complicated intra-abdominal infections * Complicated skin and skin structure infections * Community-acquired pneumonia * Nosocomial pneumonia * Febrile neutropenia (when used in combination with an antipseudomonal agent) * **Note:** Coverage of specific organisms depends on local susceptibility patterns. ## Adult Dosing * **Standard Dose:** 3.375 grams (3g piperacillin/0.375g tazobactam) intravenously every 6 hours. * **Severe/Nosocomial Infections:** 4.5 grams (4g piperacillin/0.5g tazobactam) intravenously every 6 or 8 hours. * **Duration:** Typically 7-14 days, guided by severity of infection, clinical response, and pathogen susceptibility. * **Maximum Daily Dose:** Not explicitly defined, but prolonged or high-dose therapy should be guided by clinical response and renal function. ## Pediatric Dosing * **Children < 12 years:** Dosing varies by indication and weight. Often dosed based on piperacillin component. * **Intra-abdominal infections:** 90 mg/kg (piperacillin component) IV every 8 hours. * **Febrile neutropenia:** 90 mg/kg (piperacillin component) IV every 6 hours. * **Children ≥ 12 years:** Same as adult dosing (3.375 g or 4.5 g IV every 6 or 8 hours). * **Note:** Pediatric dosing can be complex and should be guided by specific guidelines and local protocols. ## Dose Adjustments * **Renal Impairment:** Dose reduction and/or increased interval based on creatinine clearance (CrCl). * CrCl 20-40 mL/min: Administer usual dose every 8 hours. * CrCl < 20 mL/min: Administer usual dose every 12 hours. * **Hemodialysis:** Administer usual dose every 8 hours and supplement with an additional dose of 2.25 g after each dialysis session. * **Hepatic Impairment:** No specific dose adjustments are typically required, but caution is advised. ## Contraindications * Hypersensitivity to piperacillin, tazobactam, other penicillins, or any component of the formulation. * History of a severe allergic reaction (e.g., anaphylaxis) to beta-lactam antibiotics. ## Adverse Effects * **Common:** Diarrhea, nausea, vomiting, rash, headache, insomnia, constipation. * **Serious:** * Hypersensitivity reactions, including anaphylaxis. * Clostridioides difficile-associated diarrhea. * Seizures (more common with high doses or renal impairment). * Hepatotoxicity. * Hematologic changes (neutropenia, thrombocytopenia, eosinophilia, leukopenia). * Electrolyte imbalances. * Interstitial nephritis. ## Key Drug Interactions * **Probenecid:** May increase and prolong piperacillin serum concentrations. * **Neuromuscular blocking agents (e.g., vecuronium):** Piperacillin may prolong the neuromuscular blockade. * **Warfarin:** May decrease the efficacy of warfarin; monitor INR closely. * **Methotrexate:** May decrease methotrexate clearance; monitor methotrexate levels. ## Monitoring * **Renal function:** Essential for dose adjustment and monitoring for interstitial nephritis. * **Liver function tests:** Baseline and periodically, especially with prolonged therapy. * **Complete blood count:** Monitor for hematologic abnormalities. * **Electrolytes:** Monitor for imbalances, especially with prolonged therapy or renal impairment. * **Signs and symptoms of infection:** Clinical response to therapy. * **Signs and symptoms of hypersensitivity reactions.** * **Stool for C. difficile testing** if diarrhea occurs. ## Clinical Pearls * Piperacillin/tazobactam is a workhorse antibiotic with broad-spectrum activity, including coverage against many Gram-positive, Gram-negative (including *Pseudomonas aeruginosa*), and anaerobic organisms. * Tazobactam enhances piperacillin activity by inhibiting beta-lactamases, but does not cover all beta-lactamases (e.g., ESBLs, carbapenemases). * Dosing and duration should be tailored to the specific infection, patient factors (renal function), and local antimicrobial susceptibility data. * Reconstituted solutions are typically stable for 24 hours at room temperature or 48 hours refrigerated. Follow manufacturer guidelines for preparation and storage. * Administer IV infusion over at least 30 minutes to reduce risk of infusion-related reactions. *** *Disclaimer: This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant clinical guidelines for complete and up-to-date details regarding drug indications, contraindications, warnings, precautions, adverse effects, drug interactions, and dosing before making any treatment decisions.*